These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Antiphospholipid Syndrome--Not a Noninflammatory Disease. de Groot PG; Urbanus RT Semin Thromb Hemost; 2015 Sep; 41(6):607-14. PubMed ID: 26276935 [TBL] [Abstract][Full Text] [Related]
46. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. de Jesús GR; Benson AE; Chighizola CB; Sciascia S; Branch DW Lupus; 2020 Oct; 29(12):1601-1615. PubMed ID: 32883160 [TBL] [Abstract][Full Text] [Related]
47. Antiphospholipid syndrome - an update. Linnemann B Vasa; 2018 Oct; 47(6):451-464. PubMed ID: 30205764 [TBL] [Abstract][Full Text] [Related]
48. Antiphospholipid syndrome: 30 years and our contribution. Koike T Int J Rheum Dis; 2015 Feb; 18(2):233-41. PubMed ID: 25524556 [TBL] [Abstract][Full Text] [Related]
49. Detection of multiple annexin autoantibodies in a patient with recurrent miscarriages, fulminant stroke and seronegative antiphospholipid syndrome. Scholz P; Auler M; Brachvogel B; Benzing T; Mallman P; Streichert T; Klatt AR Biochem Med (Zagreb); 2016; 26(2):272-8. PubMed ID: 27346975 [TBL] [Abstract][Full Text] [Related]
50. Clinical implications of the detection of antibodies directed against domain 1 of β2-glycoprotein 1 in thrombotic antiphospholipid syndrome. Montalvão S; Elídio PS; da Silva Saraiva S; de Moraes Mazetto B; Colella MP; de Paula EV; Appenzeller S; Annichino-Bizzacchi J; Orsi FA Thromb Res; 2016 Dec; 148():32-37. PubMed ID: 27770664 [TBL] [Abstract][Full Text] [Related]
51. Post-translational oxidative modification of β2-glycoprotein I and its role in the pathophysiology of the antiphospholipid syndrome. Mirarabshahi P; Abdelatti M; Krilis S Autoimmun Rev; 2012 Sep; 11(11):779-80. PubMed ID: 22240262 [TBL] [Abstract][Full Text] [Related]
52. Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells. Pierangeli SS; Harris EN Lupus; 2003; 12(7):539-45. PubMed ID: 12892395 [TBL] [Abstract][Full Text] [Related]
53. [Following 90 patients with antiphospholipid syndrome with antibody titers and correlations with clinical manifestations: symptoms of the disease, a new antibody and correlations with clinical manifestations in the Israeli population]. Marai I; Levi Y; Godard G; Shoenfeld Y Harefuah; 2001 Jun; 140(6):495-500, 565. PubMed ID: 11420848 [TBL] [Abstract][Full Text] [Related]
54. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. Cabiedes J; Cabral AR; Alarcón-Segovia D J Rheumatol; 1995 Oct; 22(10):1899-906. PubMed ID: 8991989 [TBL] [Abstract][Full Text] [Related]
55. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Krause I; Blank M; Fraser A; Lorber M; Stojanovich L; Rovensky J; Shoenfeld Y Immunobiology; 2005; 210(10):749-54. PubMed ID: 16325493 [TBL] [Abstract][Full Text] [Related]
56. The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Salmon JE; Girardi G; Lockshin MD Nat Clin Pract Rheumatol; 2007 Mar; 3(3):140-7; quiz 1 p following 187. PubMed ID: 17334336 [TBL] [Abstract][Full Text] [Related]
57. Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. George J; Blank M; Levy Y; Meroni P; Damianovich M; Tincani A; Shoenfeld Y Circulation; 1998 Mar; 97(9):900-6. PubMed ID: 9521339 [TBL] [Abstract][Full Text] [Related]
58. Distinguishing features of anti-beta2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome. Arvieux J; Renaudineau Y; Mane I; Perraut R; Krilis SA; Youinou P Thromb Haemost; 2002 Apr; 87(4):599-605. PubMed ID: 12008941 [TBL] [Abstract][Full Text] [Related]
59. Crassolide Suppresses Dendritic Cell Maturation and Attenuates Experimental Antiphospholipid Syndrome. Lin CC; Chang YK; Lin SC; Su JH; Chao YH; Tang KT Molecules; 2021 Apr; 26(9):. PubMed ID: 33923336 [TBL] [Abstract][Full Text] [Related]
60. Determination of clinically significant tests for antiphospholipid antibodies and cutoff levels for obstetric antiphospholipid syndrome. Kitaori T; Sugiura-Ogasawara M; Oku K; Papisch W; Ebara T; Ozaki Y; Katano K; Atsumi T Lupus; 2015 Dec; 24(14):1505-19. PubMed ID: 26162683 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]